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Abstract
Background: During uncontrolled HIV disease, both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptor
expression are increased. Enhanced TRAIL sensitivity is due to TRAIL receptor up-regulation induced by gp120. As a result of
successful antiretroviral therapy TRAIL is down-regulated, and there are fewer TRAIL-sensitive cells. In this setting, we
hypothesized that all cells that contain virus, including those productively- and latently-infected, have necessarily been
‘‘primed’’ by gp120 and remain TRAIL-sensitive, whereas uninfected cells remain relatively TRAIL-resistant.
Methods and Findings: We evaluated the immunologic and antiviral effects of TRAIL in peripheral blood lymphocytes
collected from HIV-infected patients with suppressed viral replication. The peripheral blood lymphocytes were treated with
recombinant TRAIL or an equivalent amount of bovine serum albumin as a negative control. Treated cells were then
analyzed by quantitative flow cytometry, ELISPOT for CD4+ and CD8+ T-cell function, and limiting dilution microculture for
viral burden. Alterations in the cytokine milieu of treated cells were assessed with a multiplex cytokine assay. Treatment
with recombinant TRAIL in vitro reduced viral burden in lymphocytes collected from HIV-infected patients with suppressed
viral load. TRAIL treatment did not alter the cytokine milieu of treated cells. Moreover, treatment with recombinant TRAIL
had no adverse effect on either the quantity or function of immune cells from HIV-infected patients with suppressed viral
replication.
Conclusions: TRAIL treatment may be an important adjunct to antiretroviral therapy, even in patients with suppressed viral
replication, perhaps by inducing apoptosis in cells with latent HIV reservoirs. The absence of adverse effect on the quantity
or function of immune cells from HIV-infected patients suggests that there is not a significant level of ‘‘bystander death’’ in
uninfected cells.
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Introduction
The role of tumor necrosis factor-related apoptosis inducing
ligand (TRAIL) during HIV infection remains controversial.
Exploitation of TRAIL signaling and subsequent TRAIL-induced
apoptosis may have therapeutic value by promoting the death of
cells which harbor latent HIV reservoirs in HIV-infected patients.
Consistent with this hypothesis, leucine-zipper TRAIL and
agonistic anti-TRAIL receptor antibodies [1] or autologous
activated NK cells expressing TRAIL [2] induced in vitro apoptosis
of monocyte-derived macrophages and peripheral blood lympho-
cytes from HIV-infected patients, resulting in reduced viral burden
following limiting dilution microculture. In all cases tested TRAIL
treatment of cells led to reduced viral burden, even to undetectable
levels, whereas untreated cells produced large amounts of both
HIV RNA and p24 antigen [1,2]. Furthermore, monocyte-derived
macrophages and peripheral blood lymphocytes collected from
uninfected donors did not die following treatment with leucine-
zipper TRAIL [1]. However, in order for TRAIL therapy to have
clinical utility, it must have an acceptable safety profile in HIV
patients.
Despite evidence that TRAIL is not toxicto uninfectedcells other
models have been proposed that suggest TRAIL-induced apoptosis
contributes to the ‘‘bystander death’’ of uninfected CD4+ T cells. In
these models productive HIV infection enhances TRAIL produc-
tion, and gp120 ‘‘priming’’ of uninfected T cells induces TRAIL
sensitivity. For instance, increased levels of mRNA for IFN-a,
TRAIL and TRAIL receptor R2 (TRAIL-R2) were measured in
the tonsils of patients with progressive HIV disease compared to
those with nonprogressive disease, and tonsils from uninfected
patients did not contain TRAIL or TRAIL-R2 mRNA [3]. Because
HIV-induced expression of TRAIL is dependent on IFN-a which is
primarily produced by plasmacytoid dendritic cells (pDC) [4], a
model has been suggested in which HIV induces plasmacytoid
dendritic cells to produce INF-a [4]. IFN-a then induces expression
of TRAIL in uninfected CD4+ T cells [4]. Subsequent binding of
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expression of TRAIL-R2 [5] leading to apoptosis of the cells and
their neighbors via ‘‘bystander death’’ [4].
A second model of TRAIL-mediated death of uninfected cells
has been proposed. Massive apoptosis of uninfected CD4+ T cells
was observed in the spleens of HIV-infected mice transplanted
with human peripheral blood lymphocytes, and the apoptotic cells
co-localized with TRAIL-expressing T cells [6]. A subsequent
study showed that treatment of uninfected primary human
macrophages with HIV-1 Tat protein induced TRAIL expression
to levels comparable to those measured following HIV infection
[7]. Based on these data a model was proposed in which
extracellular Tat produced by HIV-infected cells, induces TRAIL
expression in uninfected macrophages [7] and subsequent
interaction of these cells with uninfected gp120 ‘‘primed’’ CD4+
T cells results in increased TRAIL sensitivity [5] and consequent
TRAIL-mediated apoptosis in uninfected T cells.
However, the definitive experiment using antagonistic anti-
TRAIL antibodies has not been tested in these models. In a model
of HIV-infected macrophage killing of uninfected T cells anti-Fas
antibodies abrogate apoptosis in the uninfected cells [8,9], yet
antagonistic anti-TRAIL antibodies have no such effect (Unpub-
lished results, ADB). Furthermore, in HIV-infected human
lymphocyte aggregate cultures containing pDC, antagonistic
anti-TRAIL antibodies did not alter uninfected CD4+ T-cell
death [10], thereby raising questions as to the true relevance of
TRAIL in bystander killing. Moreover, the latter model has been
challenged by more recent data demonstrating that HIV Tat
increases c-FLIP and downregulates caspase 10 in T lymphocytes
[11] and increases Bcl-2 in monocytes [12], each leading to
inhibition of TRAIL-mediated apoptosis in each cell type. Lastly, a
potential role for TRAIL causing immune cell depletion is further
argued against by the recent finding that HIV-infected macro-
phages upregulate Bfl-1 and Mcl-1 as a counter-regulatory
mechanism to resist the cytotoxic effects of TRAIL [13].
Even without such limitations, neither model is mutually
exclusive with our previous data showing that uninfected
macrophages and lymphocytes do not die following treatment
with leucine-zipper TRAIL [1]. Although TRAIL may account for
a degree of bystander killing of uninfected CD4+ T cells in patients
with unsuppressed replication, it does not preclude a therapeutic
role for TRAIL in suppressed patients. Indeed, in suppressed
patients with no detectable viral load in the plasma, HIV DNA
can be detected in the lymph nodes and peripheral blood
lymphocytes (PBLs), reflecting a pool of latently-infected cells
established very early during primary HIV infection [14]. While
the frequency of these latently-infected cells is approximately 16
per million PBLs [15], thus precluding direct experimentation with
this important pool of cells, their persistence despite effective
antiretroviral therapy highlights the need for additional strategies
of therapy. Since all infected cells, including latently-infected cells
which revert to a resting memory phenotype, have necessarily
contacted gp120, all such cells would be predicted to have
enhanced TRAIL sensitivity. In a suppressed setting lack of
replication would predictably reduce TRAIL production, and
indeed TRAIL levels are directly proportional to HIV viral load
[16,17]. However, both productively- and latently-infected cells,
but very few uninfected cells, should maintain TRAIL sensitivity.
Consequently, exogenous TRAIL might selectively target and kill
those infected cells. The purpose of the current study was to
validate the antiviral properties of TRAIL in suppressed patients
and to evaluate whether additional, significant bystander death
occurs and deleteriously affects other parts of the immune system.
Results
Human peripheral blood lymphocytes (PBLs) obtained from
HIV-negative donors were stimulated with PHA and IL-2 and
tested for the cytotoxic response to recombinant TRAIL
(skTRAIL) (Fig. 1). A dose of 5 ng/ml of skTRAIL was chosen
for subsequent experiments given that this was the maximum dose
of skTRAIL that had only limited impact on cell viability.
PBLs from HIV-uninfected donors were infected with HIV-IIIB
and the effect of TRAIL treatment on cell viability was assessed
(Fig. 2A). In these experiments, daily TRAIL treatments for ten
days had no significant effect on cumulative cell number (Fig. 2A).
However, since TRAIL treatment can result in both apoptosis and
proliferation, it is unclear whether apoptosis or proliferation
occurred in these populations or whether apoptosis occurred early
Figure 1. Effect of skTRAIL treatment on cell viability. Peripheral blood lymphocytes (PBLs) were collected from HIV-negative donors,
stimulated with PHA and IL-2, and treated with with skTRAIL at the indicated concentrations. Viability was assessed by trypan blue staining.
doi:10.1371/journal.pone.0003096.g001
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this possibility, cells were stained on day 0 (immediately following
HIV infection) with CFSE and proliferation assessed by compar-
ing CFSE dilution between HIV-infected but untreated, and HIV-
infected but TRAIL-treated cells (Fig. 2B).
Enhanced cell proliferation might in theory drive HIV
replication to such a degree that the antiviral effects of TRAIL
treatment might be overcome by enhanced viral replication
associated with NF-kB driven proliferation. Consequently, we
analyzed whether ten days of treatment with TRAIL maintained
the antiviral effect of TRAIL that we have previously observed in
short-term treatment studies (Fig. 2C). Indeed, in these studies,
HIV-infected but untreated cultures produced significant amounts
of p24 that were significantly reduced by treatment with 5 ng/ml
of TRAIL on a daily basis. Lastly, treatment decreased the
percentage of HIV-infected cells expressing CD69, a cell surface
marker of systemic immune activation (Fig. 2D). Altogether, these
data suggest that the pro-apoptotic effects of TRAIL on infected
cells are sufficient to overcome the proliferative effects of TRAIL
in the presumably uninfected T cell populations. Moreover, these
data suggest that combining TRAIL treatment with effective
antiretroviral therapy might be an efficient way to reduce viral
burden.
Because exogenous TRAIL treatment may alter the cytokine
milieu of treated cells, multiplex cytokine assays were performed
using culture supernatants from cells collected from HIV-infected
donors and treated with TRAIL. In comparison to either
untreated cells or cells treated with bovine serum albumin
(BSA), HIV-infected cells treated with TRAIL showed no
biologically significant alterations in cytokine expression. Negligi-
ble changes in IL-10 expression were detected following TRAIL
treatment of cells collected from 4 HIV-infected patients (Fig. 3).
However, the magnitude of change was minimal. For example, IL-
10 expression decreased by only 1.37 pg/ml following TRAIL
treatment when compared to untreated cells. Similar negligible
decreases were detected in IL-8 expression following TRAIL
Figure 2. Effects of skTRAIL treatment following in vitro HIV infection of PBLs from uninfected donors. PBLs were collected from HIV-
negative donors and infected with HIV-IIIB prior to treatment with skTRAIL. The effects on cell count (A), proliferation as assessed by CFSE dilution (B),
p24 production (C), and CD69 expression (D) were measured.
doi:10.1371/journal.pone.0003096.g002
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expression among the other cytokines included in the multiplex
assay, including: IL-1ra, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9,
IL-12 (p70), IL-13, IL-15, IL-17, eotaxin, basic FGF, G-CSF,
GM-CSF, IFN-c, IP-10, MCP-1, MIP-1a, MIP-1b, PDGF-BB,
RANTES, INF-a, and VEGF (data not shown). Similar results
were measured following TRAIL treatment of PBLs from an
uninfected donor (data not shown).
In order to determine if exogenous TRAIL treatment has
beneficial antiviral properties, PBLs were isolated from 6 HIV-
infected individuals with suppressed levels of viral replication. All
HIV-infected subjects had CD4+ counts greater than 150 cells/
mL and had HIV viral loads that were suppressed to ,50 (Fig. 4).
The PBLs were then treated with 5 ng/mL of TRAIL or equal
molar concentrations of BSA and cultured with labeled feeder cells
in a limiting dilution microculture. Consistent with prior results
[1,2] and as shown in Figure 4, PBLs from all six individuals had
significantly lower infectious units per million (IUPM) when
cultured with TRAIL versus those cultured with BSA. PBL
cultures from two individuals decreased HIV IUPM to undetect-
able levels after TRAIL treatment, together demonstrating that
exogenous TRAIL therapy in vitro decreases HIV viral burden in
PBLs from HIV-infected individuals with baseline suppressed HIV
viral loads.
The antiviral effects of exogenous TRAIL treatment during
HIV infection will only be useful if the TRAIL targets and kills
HIV-infected cells, but does not affect the remainder of the
immune system. Therefore, PBLs from the 6 HIV-infected
individuals were cultured with 5 ng/mL of TRAIL or BSA to
determine if TRAIL altered T cell, B cell, or NK cells numbers, or
Figure 3. IL-10 expression following treatment of HIV-infected PBLs with skTRAIL, a representative example of results obtained
from assays with the Bio-Plex human cytokine 27-plex panel. PBLs were collected from 4 HIV-infected donors and 1 uninfected control. Cells
received either no treatment or were treated with either BSA (5 ng/ml) or skTRAIL (5 ng/ml). Following 24 h of culture, supernatants were collected
for measurement of cytokine expression. Values are presented as relative fluorescence units, reflecting a range of concentrations from 0.08 to
2.01 pg/ml based on extrapolation from a standard curve generated with known concentrations of IL-10 at the time of analysis.
doi:10.1371/journal.pone.0003096.g003
Figure 4. Superkiller TRAIL decreases HIV viral burden in PBLs from HIV infected individuals. PBLs from HIV infected individuals were
isolated and treated with skTRAIL or BSA in a limiting dilution micro co-culture. HIV viral burden is reported as infectious units per million.
doi:10.1371/journal.pone.0003096.g004
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TRAIL treatment did not alter the percent of total T lymphocytes,
CD4+ or CD8+ T cells, B cell or NK cell percentages, as
determined by flow cytometry (top panel). Flow cytometry for the
surface markers CD45 RO+/RA2 and CD45RO2/RA2
demonstrated that TRAIL treatment did not alter CD4+ or
CD8+ memory or naı ¨ve populations (Fig. 5A, bottom panel).
Furthermore, ELISPOT analysis showed no difference between
CD4+ recall responses to the CMV pp65 peptide or the CD8+
CEF peptide in cells cultured with TRAIL or control protein
(Fig. 5B). Thus, suggesting that exogenous TRAIL treatment
effectively decreases HIV viral burden in PBLs from HIV-infected
individuals and has no adverse effects on immune cell numbers or
function.
Discussion
The present study shows that recombinant TRAIL can reduce
HIV viral burden, even in lymphocytes collected from HIV-
infected patients with a suppressed viral load, suggesting that
TRAIL treatment may be an important adjunct to antiretroviral
therapy, perhaps by inducing apoptosis in cells with latent HIV
reservoirs.
TRAIL treatment did not alter the cytokine milieu of treated
cells. Of equal significance, the present study shows that treatment
with recombinant TRAIL had no adverse effect on either the
quantity or function of immune cells from HIV-infected patients
with suppressed viral replication, which suggests that there is not a
significant level of ‘‘bystander death’’ in uninfected cells from these
suppressed patients. These data challenge suggested models to the
contrary, which have not yet been definitively tested with
antagonistic anti-TRAIL antibodies to show that TRAIL inhibi-
tion abrogates apoptosis in uninfected cells. The results of these
quantitative and functional assays in lymphocytes from infected
patients supplement an earlier observation that treatment with
recombinant TRAIL did not induce apoptosis in peripheral blood
lymphocytes collected from uninfected donors [1]. Furthermore,
these results are consistent with a growing body of preclinical and
clinical trial data which have not shown significant toxicity with
use of recombinant, untagged TRAIL in HIV-negative cancer
patients [18]. A prior study raised concern after showing that
treatment with polyhistidine-tagged TRAIL was toxic to primary
human hepatocytes (PHH) [19]. However, it is now widely
accepted that the toxicity was due to formation of highly
oligomerized aggregates of this tagged version of TRAIL, which
are toxic to normal tissues through enhanced multimerization of
TRAIL receptors [20]. Indeed, subsequent studies have shown
that three tagged versions of TRAIL were toxic to PHH, whereas
untagged TRAIL was not [21]. Moreover, we have observed
minimal toxicity of leucine-zipper TRAIL to freshly isolated PHH
when used at the doses in the current report (Personal observation,
ADB and SAR).
Figure 5. Exogenous superkiller TRAIL does not cause deleterious effects on immune cell numbers or function. PBLs from HIV infected
subjects were cultured with skTRAIL or BSA and analyzed for percent of T, B and NK cells (A, top panel), and percent CD4+ and CD8+ memory and
naı ¨ve T cells (A, bottom panel) by flow cytometry. Cultured PBLs were also analyzed for CD4 and CD8 recall responses by ELISPOT (B).
doi:10.1371/journal.pone.0003096.g005
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induces reductions in HIV viral load is uncertain. TRAIL-
mediated apoptosis may play a role in the cytolytic clearance of
virus-infected cells, and the gene encoding TRAIL is one of the
earliest induced by interferons in response to viral infection [22].
Alternatively, induction of TRAIL signaling may promote
reductions in HIV viral load through increased immune
activation. Indeed, TRAIL signaling has been shown to induce
non-apoptotic pathways through the activation of NF-kB, PKB/
Akt, and MAPK [23]. However, our data demonstrating
decreased CD69 expression following TRAIL treatment of PBLs
infected in vitro with HIV raises uncertainty regarding this
hypothesis. Because of the uncertainty of the mechanism that
links induction of TRAIL signaling with subsequent reductions in
HIV viral load and the potential therapeutic value that may be
gained by such an understanding, the use of TRAIL in the
treatment of HIV infection is an obvious and logical candidate for
further study.
Materials and Methods
Patient consent and protocol
Patient samples were obtained following informed consent, the
protocol of which was reviewed and approved by the Mayo Clinic
institutional review board.
TRAIL
SuperKillerTRAIL (Axxora Life Sciences, Inc.) and bovine
serum albumin (Sigma) were each diluted in phosphate-buffered
saline to a working stock of 100 ng/ml prior to use in experiments
Cells
Human peripheral blood lymphocytes (PBLs), obtained from
healthy, normal donors, were stimulated with PHA 5 mg/ml.
Then IL-2 was added (20 U/ml) and cells were plated (10
5 cells
per well in 200 ml) for testing of the cytotoxic response to
treatment with TRAIL. Unstimulated PBLs from healthy, normal
donors were used for in vitro HIV infection as described below.
Unstimulated PBLs from 6 HIV-infected patients with suppressed
viral replication were used in experiments to determine if
exogenous TRAIL treatment has beneficial antiviral effects. All
cells were isolated from whole blood samples and were enriched
for PBLs using Ficoll-Paque (GE Healthcare, Ltd.) density gradient
centrifugation according to the manufacturer’s recommendations.
HIV infection of PBLs from healthy donors
Unstimulated (quiescent/resting, day 0–5) human CD4+ T-
lymphocytes, obtained by magnetic beads separation from healthy,
normal donors, were infected with HIV-1 IIIB, defective for the
regulatory genes vpr and nef. After five days in culture cells were
stimulated with PHA (5 mg/ml), then at day 7 IL-2 (20 U/ml) was
added (stimulated, day 6–10). A 5 ng/ml concentration of TRAIL
was used in the experiments. At day 10 cells and supernatants
were harvested and HIV-1 p24 antigen was measured by ELISA.
Viability of cells was investigated at day 10 by trypan blue staining.
Proliferation of CD4+ T cells was studied by staining the cells with
carboxyfluorescein diacetate-succinimidyl ester (CFSE) at day 0
(immediately after infection). Activation was evaluated by studying
the expression of CD69.
Multiplex cytokine assays
CD4+ T lymphocytes were isolated from whole blood samples
collected from 4 HIV-infected patients with suppressed viral
replication and 1 healthy, uninfected control subject. Enrichment
for CD4+ cells was achieved through the use of the RosetteSep
human CD4+ T cell enrichment cocktail (StemCell Technologies)
according to the manufacturer’s protocol. Following isolation,
5610
6 CD4+ T lymphocytes from each subject were resuspended
in 500 ml of fresh RPMI media and incubated at physiologic
conditions for 24 hours without treatment, or with either bovine
serum albumin (5 ng/ml) or TRAIL (5 ng/ml). Following
incubation, supernatant from each experiment was collected and
residual cells were removed by centrifugation. Supernatants were
then used in muliplex cytokine assays using the Bio-Plex Human
Cytokine 27-plex Panel (Bio-Rad Laboratories) according to the
manufacturer’s instructions. Samples were analyzed on a Luminex
suspension array system (Bio-Rad Laboratories) and subsequently
quantitated using Bio-Plex Manager software. (Bio-Rad Labora-
tories), each according to the manufacturer’s instructions.
ELISPOT assays
Peripheral blood lymphocytes were isolated from 6 HIV-
infected patients with suppressed viral replication and treated with
5 ng/mL of TRAIL or an equivalent amount of BSA. Frequencies
of antigen-specific CD4+ and CD8+ T cells were estimated by
primary IFN-c ELISPOT assays. Briefly, CD4+ and CD8+ T cells
were enriched from peripheral blood lymphocytes by sequential
positive selections with anti-CD4 and anti-CD8 antibody-coated
magnetic particles (Miltenyi Biotec). The purity of fractions was
routinely monitored and was consistently greater than 90%. CD4+
and CD8+ T cells were stimulated with autologous antigen-
presenting cells (non-T cell) pulsed with CMV pp65 peptide and
the CMV CEF Control Peptide Pool, respectively. The respon-
der:stimulator combinations were cultured in microtiter plates
coated with anti-IFN-c antibody (Mabtech) for two days after
which the cells were washed out and replaced with biotinylated
anti-IFNc antibody (Mabtech). Streptavidin-conjugated horserad-
ish peroxidase (Vector Laboratories) was added followed by AEC
substrate for spot development.
Flow cytometry
Peripheral blood lymphocytes were isolated from 6 HIV-
infected patients with suppressed viral replication and treated with
5 ng/mL of TRAIL or an equivalent amount of BSA. CD3+,
CD4+, and CD8+ T cells, CD19+ B-cells and NK (CD16+56+)
were quantitated using a 6-color flow cytometric assay with
specific monoclonal antibodies for each marker. The assay utilized
an FDA-approved panel of reagents (BD Multitest, BD BioSci-
ences) on the BD FACS Canto flow cytometer (BD BioSciences).
The assay was performed using 1 ml whole blood collected in an
EDTA tube in a 6-color Lyse-no wash procedure. Both the
percent of cells in each subpopulation as well as the absolute
counts per ml of blood was reported for CD45+ lymphocytes, and
the T-cell, B-cell and NK-cell populations. The absolute counts
were determined using internal bead standards and data analysis
was performed with the BD FACS Canto clinical software (BD
BioSciences). Manual gating of populations was performed where
needed if the software-assigned gate was deemed to be inaccurate.
Limiting dilution microculture assays
Viral burden was estimated using limiting dilution microculture
assays, followed by maximum likelihood estimates as previously
described [24]. We used the maximum available number of cells in
each co-culture for each patient. The starting cell concentrations
ranged from 3.4610
6 to 5.0610
7 cells. Following overnight
TRAIL or BSA treatment, cells were washed three times and
then co-incubated with irradiated feeder cells for 14 days. On day
14, p24 and viral RNA levels were measured. p24 antigen was
Effect of TRAIL on HIV Burden
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Life Sciences Products). In independent experiments we deter-
mined that TRAIL treatment does not impair the ability of resting
T cells to become activated (data not shown).
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